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Abbreviations used in this paper: ACNU = 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea; anti-NF-1GRP(N) = anti-NF1 gene-related peptide (clone N); ATRA = all-transretinoic acid; dbcAMP = dibutyryl cyclic adenosine monophosphate; FBS = fetal bovine serum; GDP = guanosine diphosphate; GFAP = glial fibrillary acidic protein; GTP = guanosine triphosphate; IC 50 = 50% inhibition concentration; MEM = minimum essential medium; MGMT = O6-methylguanine-DNA methyltransferase; mRNA = messenger RNA; MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NF1 = neurofibromatosis Type 1; NF1-GRD = NF1 gene-related domain; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; SSCP = single-strand conformational polymorphism. tion cascades. 26 The signals below Ras are attenuated when Ras-GTP returns to Ras-GDP, and a GTPase-activating protein, such as neurofibromin, plays an important role in this process. 13 Loss of neurofibromin in NF1 tumor cells results in loss of the negative control mechanism of the Ras signal transduction pathways and uncontrolled proliferative signals to the nuclei. 5, 11, 13 The NF1 gene is extremely large, spanning approximately 350 kb, and there are no "hot spots" for mutation. 6, 13, 20 A large variety of mutations have been discovered in the NF1 gene in patients with NF1, including single base mutations and various mutations such as deletions, insertions, splicing errors, and translocations. 4, 6, 13 In addition, the high sporadic incidence of NF1 suggests that the gene is highly mutable. 13 It has been reported that there are at least two types of NF1-GRD mRNA isoforms generated by the alternative splicing mechanism. 35 Type II has an insertion of 63 nucleotides in the center of the Type I NF1-GRD mRNA isoform. The relative abundance of these two isoforms is modulated differentially during neuronal and embryonal cell differentiation, suggesting that neurofibromin functions as an important cell differentiation factor. 13, 35, 41 We have established and characterized a novel astrocytoma cell line, TM-31, derived from a tumor obtained in a patient with NF1. The TM-31 cells exhibit reduced expression of neurofibromin. In addition, anchorage-dependent and -independent growth of TM-31 cells have been inhibited by the farnesyltransferase inhibitor, which inhibits posttranslational modification of Ras-GTP and prevents downstream signaling. From these results, we can infer that decreased neurofibromin expression and concomitant Ras activation may be important to the growth and transformed phenotype of TM-31 cells. Although immortalized human malignant peripheral nerve sheath tumor cell lines derived from tumors in patients with NF1 have been reported, 17 to date there has been no report of an immortalized astrocytoma cell line derived from those obtained in a patient with NF1. We describe the unique characteristics of this cell line and discuss the pathogenesis of NF1-derived malignant astrocytoma.
Materials and Methods

Original Tumor
A cell line, TM-31, was established from a surgical specimen removed from an anaplastic astrocytoma. The original tumor had been excised in a 42-year-old woman with the typical cutaneous manifestation of café-au-lait spots and numerous neurofibromas. The diagnosis of NF1 had been established in the patient at puberty. At the time of presentation, the patient was experiencing worsening headache and gait disturbance, which had developed 1 month before admission. Computerized tomography and magnetic resonance imaging demonstrated a large brain tumor extending from the genu of the corpus callosum to the bilateral frontal lobe, with typical subarachnoid tumor dissemination into the cerebellopontine angle. The patient underwent a right frontal craniotomy and tumor biopsy sampling. Histopathological analysis of a surgical specimen revealed a highly cellular tumor with marked nuclear and cytoplasmic pleomorphism (Fig. 1 left) . Immunohistochemical analysis of the biopsy specimen revealed a large positive reaction for GFAP in the cytoplasm of gemistocytic neoplastic astrocytes (Fig. 1 center) . There was no area of pseudopalisading or necrosis and, thus, a diagnosis of anaplastic astrocytoma was made. The patient died 9 days after the operation. The specimen obtained at autopsy displayed a highly anaplastic glial tumor with vascular proliferation, typical necrosis, and pseudopalisades, which was compatible with the diagnosis of glioblastoma multiforme (Fig. 1 right) . General autopsy revealed numerous cutaneous neurofibromas, neurofibromas at the right C-1 nerve root and the right brachial plexus, multiple hyperplastic foci at the bilateral adrenal medullae, and follicular adenoma of the thyroid gland.
Cell Culture Method
The surgical specimen was washed repeatedly with PBS without Ca ++ and Mg less-steel mesh were diluted with Eagle's MEM containing 10% FBS, and 10 6 cells were plated onto 60-mm plastic dishes. The cultures were incubated in a humidified atmosphere of 5% CO 2 in air at 37˚C. The medium was changed twice a week and subcultured with 0.05% trypsin before confluency. After 50 passages, we named this cell line TM-31. A growth curve was generated, and the cell doubling time was determined using TM-31 cells at different passage levels by counting viable cells daily with the trypan blue exclusion method.
Immunocytochemical Analysis
Immunocytochemical stains were applied to TM-31 cells grown on cover slips by using the labeled streptavidin-biotin staining technique. Cells at high passages (Ͼ 200) were fixed with 4% paraformaldehyde for 15 minutes. After incubation with 3% hydrogen peroxide solution to block endogenous peroxidase activity and 1% bovine albumin in PBS to block nonspecific binding of antibodies, the cover slips were separately treated overnight at 4˚C by using anti-GFAP and antivimentin mouse monoclonal antibodies (1:1500-2000 dilution) and anti-cow S-100 rabbit polyclonal antibody (1:50 dilution). After the cells had been washed with PBS, biotin-conjugated rabbit anti-mouse or goat anti-rabbit immunoglobulin G and streptavidin-biotin-peroxidase complex were each applied for 30 minutes. The color was developed by addition of diaminobenzidine (0.06%).
Immunoblot Analysis
Immunoblot analyses were performed to detect GFAP and neurofibromin. For the GFAP analysis, cells at high passages were harvested in ice-cold Triton X-100 lysis buffer, which contained 1% Triton X-100 and 50 mM Tris-HCl. After this procedure, the lysates were centrifuged at 14,000 rpm for 30 minutes. The supernatant proteins were removed. The Triton X-100 insoluble pellet was dissolved in 4% sodium dodecyl sulfate with 50 mM Tris-HCl at 100˚C for 10 minutes and was subjected to GFAP immunoblotting. For neurofibromin detection, a modified RIPA buffer (150 mM NaCl/50 mM Tris HCl [pH 7.5], 1% Nonidet P-40, 0.25% sodium deoxycholate, 2 mM ethyleneglycol-bis (␤-aminoethylether)N,NЈ-tetraacetic acid, 1 mM phenylmethylsulfonate, 1 mM leupeptin, 0.1 M aprotinin) was used as the cell lysis buffer. 15 The supernatant proteins of the lysates were subjected to neurofibromin immunoblotting. The amount of protein was determined using a commercially available protein assay kit. Equal amounts (50 g) of proteins were prepared by boiling in a sample buffer (62.5 mM Tris-HCl [pH 6.8], 2% sodium dodecyl sulfate, 10% glycerol, 5% 2-mercaptoethanol, and 0.001% bromophenol blue). The proteins were loaded onto 7 to 10% denaturing polyacrylamide gel for electrophoresis and transferred to polyvinylidene difluoride membranes by semidry electrotransfer. Transfer times lasted 1 hour for GFAP and 6 hours for neurofibromin. After blocking nonspecific binding for 1 hour in PBS/0.1% Tween-20 containing 5% (wt/vol) skim milk powder, the membranes were incubated for 1 hour with mouse anti-GFAP monoclonal antibody (1:2000 dilution) or rabbit anti-NF-1GRP (N) polyclonal antibody (1:1000 dilution). After the membranes had been incubated with secondary anti-rabbit or anti-mouse antibodies conjugated with horseradish peroxidase for 1 hour, the signals were detected using the a chemiluminescence detection system. Immunoblots were developed by exposure to x-ray film.
Tumorigenicity Testing
The TM-31 cells were tested for their ability to form tumors in the athymic mouse. Exponentially growing cells were trypsinized and resuspended in PBS, after which 1 to 2 ϫ 10 6 cells were injected subcutaneously into the lateral abdominal walls of 5-week-old male athymic mice (Balb/c nu/nu strain).
Chromosome Analysis
Exponentially growing TM-31 cells at passage 210 were incubated for 1.5 hours at 37˚C in the presence of Colcemid (0.1 g/ml). Treated cells were trypsinized, washed, and resuspended in 0.075 M KCl for 30 minutes at 37˚C, after which they were fixed with acetic alcohol. Chromosome spreads were made by dropping the cell suspension onto a clean glass slide and staining it with 2.5% Giemsa solution. Samples were examined using an immersion optic with a photomicroscope.
Mutation Analysis of the p53 Gene
To detect mutations in the p53 gene, PCR-SSCP analysis and direct sequencing were used as described previously. 3, 7, 36 The DNA of TM-31 cells from passage 240 was prepared by proteinase K digestion and phenol extraction and was subjected to PCR to amplify exons 5, 6, 7, and 8 of the p53 gene. Primer sets for amplification of the four exons of p53 were designed as follows by using fluorescence Cy-5 at the 5Ј site of primers according to GeneBank X54156: exon 5, 5Ј-TTCCTCTTCCTACAGTACTCC-3Ј and 5Ј-GCCCCAGCTGCTCACCATCGC-3Ј; exon 6, 5Ј-CACTGA-TTGCTCTTAGGTCTG-3Ј and 5Ј-AGTTGCAAACCAGACCTC-AGG-3Ј; exon 7, 5Ј-CCAAGGCGCACTGGCCTCATC-3Ј and 5Ј-TCAGCGGCAAGCAGAGGCTGG-3Ј; and exon 8, 5Ј-CCT-ATCCTGAGTAGTGGTAAT-3Ј and 5Ј-GTCCTGCTTGCTTAC-CTCGCT-3Ј. The thermal cycling profile consisted of a 30-second denaturation step at 94˚C, a 60-second annealing step at 60˚C (exons 5, 6, and 8) or at 70˚C (exon 7), and a 60-second extension step at 72˚C, for a total of 35 cycles. The PCR products were analyzed using electrophoresis on 5% polyacrylamide gels with an automated laser fluorescence DNA sequencer, ALFexpress. In the sequence procedure, an aliquot of the PCR product was purified using a PCR product purification kit and directly sequenced using a sequencing kit with ALFexpress. The sequence was finally compared with the wild-type p53 sequence.
Chemosensitivity Assays
Chemosensitivity tests of TM-31 cells were conducted using a colorimetric MTT assay as described previously. 33 The anticancer agents used in the present study included cisplatin, etoposide, and ACNU. In addition, the farnesyltransferase inhibitor B1620 was used to determine whether Ras activation is essential for the growth of TM-31 cells. A methyl-ester prodrug, B1620 specifically inhibits posttranslational farnesylation of the Ras protein. Cells at high passages were seeded into 96-well microplates at an initial density of 2500 cells/well in 100 l medium without antiproliferative reagents. After incubation for 24 hours, the plates were replaced with fresh media with various concentrations of anticancer drugs or B1620. The cells were treated for either 4 days with anticancer agents or 7 days with B1620. The longer exposure time was used for B1620 because B1620 is a cytostatic drug and a 4-day treatment of cells demonstrated little inhibitory effect in a preliminary MTT assay. After this procedure 50 l of PBS containing 5 mg/ml of MTT was added to the culture media and incubated for 4 hours. Thereafter, the media were gently removed and 100 l of dimethylsulfoxide was added to each well to solubilize formazan precipitate. Following agitation, the absorbance of each well was measured at a test wavelength of 550 nm.
Morphological Differentiation Induction
The induction of morphological differentiation was attempted with the differentiation agents all-transretinoic acid and dbcAMP. The ATRA was dissolved in 99.5% ethyl alcohol to make a stock solution at the concentration of 5 mM. The dbcAMP was dissolved with culture medium and sterilized with Millex-GV. Both were diluted into the growth medium to final concentrations up to 20 M ATRA and 5 mM dbcAMP.
Anchorage-Independent Growth of TM-31 Cells
A soft agar assay was performed to examine the capacity of TM-31 cells for anchorage-independent growth. The TM-31 cells were incubated in the upper layer of 0.3% agar in MEM with 10% FBS, which was overlaid on 0.5% basal agar in MEM with 10% FBS. The cultures were maintained for 2 weeks at 37˚C in a humidified atmosphere of 5% CO 2 , and cell colonies consisting of more than 20 cells were counted. Experiments were performed in quadruplicate.
Sources of Supplies and Equipment
Labeled streptavidin-biotin staining of cells was performed using an LSABkit purchased from Dako Corp. (Carpinteria, CA), which also provided the anti-cow S-100 rabbit polyclonal antibody. The anti-GFAP and antivimentin mouse monoclonal antibodies were purchased from Boehring Mannheim (Mannheim, Germany) and the rabbit anti-NF-1GRP (N) polyclonal antibody from Santa Cruz Biotechnology (Santa Cruz, CA). The secondary anti-rabbit and anti-mouse antibodies conjugated with horseradish peroxidase and the DC protein assay kit were obtained from BioRad (Hercules, CA); the Immobilon P polyvinylidene difluoride membranes and Millex- 
FIG. 3. Photomicrographs demonstrating immunocytochemical staining of TM-31 cells for vimentin (left) and S-100 protein (right).
Vimentin is abundant in the cytoplasm, especially in the perinuclear space, and S-100 protein is positive in both the cytoplasm and nuclei of the cells. Original magnification ϫ 400.
GV were obtained from Millipore (Bedford, MA). The ECL chemiluminescence detection system was purchased from Amersham (Buckinghamshire, United Kingdom), the fluorescence Cy-5 from Amersham Pharmacia Bioteck (Tokyo, Japan), the automated laser fluorescence DNA sequencer, ALFexpress, from Amersham Pharmacia Biotech (Uppsala, Sweden), and the Thermosequenase kit from Amersham (Little Chalfont, United Kingdom). The High Pure PCR Product Purification kit was acquired from Roche Molecular Biochemical Diagnostic (Mannheim, German). The B1620 was obtained from Eisai (Tsukuba, Japan) and the dimethylsulfoxide, ATRA, and dbcAMP from Sigma Chemical Co. (St. Louis, MO). The photomicroscope was purchased from Olympus and the athymic mice were provided by Japan Clear (both companies located in Tokyo, Japan).
Results
Morphological Findings and Growth Characteristics of TM-31 Cells
The TM-31 cells are fusiform and often polygonal in a sparse culture; they become spindle shaped and pile up at confluency with a loss of contact inhibition (Fig. 2) . Immunocytochemical analysis demonstrated that the TM-31 cells were negative for GFAP (data not shown) but that most cells were positive for vimentin and S-100 protein (Fig. 3) . Vimentin staining was localized predominantly in the cytoplasm, especially in the perinuclear space. The S-100 protein was localized in both the cytoplasm and nuclei. Tumor cell doubling times of TM-31 cells at Passages 50 and 220 were 65 hours and 62 hours, respectively, with the same saturation density of 6 ϫ 10 
Immunoblot Findings for GFAP and Neurofibromin in TM-31 Cells
Immunoblot analysis of the extract of TM-31 cells revealed no expression of GFAP at a molecular mass of approximately 50 kD compared with the positive control of rat brain (Fig. 4) . The TM-31 cells exhibited little expression of neurofibromin, as detected using the anti-NF-1GRP (N) polyclonal antibody (Fig. 4) . Neurofibromin expression of cells from the adult rat brain and from TM-1, a human anaplastic astrocytoma cell line, 2 was apparently higher than that of TM-31 cells.
Tumorigenicity of TM-31 Cells
Although TM-31 cells were injected into the lateral abdominal walls of six athymic mice, no tumors grew during the observation period, which lasted 2 months.
Chromosome Number
Chromosomal analysis performed at Passage 210 revealed an aneuploidy pattern (Fig. 5) . The chromosome number ranged from 67 to 165, with a modal number of 76 (Fig. 5 lower) .
Mutation of p53
An aberrant peak shift was observed in exon 7 (Fig. 6) , and direct sequencing of the exon 7 showed a p53 gene point mutation in codon 238, in which there was a nucleotide change from TGT to GGT accompanied by an associated amino acid change from cystein to glycine.
Chemosensitivity and Morphological Differentiation of TM-31 Cells
The results of the chemosensitivity tests are shown in Fig. 7 . The concentrations of anticancer agents at which the IC 50 was observed are summarized in Table 1 . The TM-31 cells were significantly resistant to ACNU but were sensitive to cisplatin, etoposide, and B1620.
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Anchorage-Independent Growth
The TM-31 cells formed colonies in soft agar, with a control plating efficiency of 0.5%. When B1620 was added to the upper agar layer at a final concentration ranging from 0.1 to 100 M, colony formation in soft agar was strongly inhibited even at the lower concentrations, as shown in Table 2 , compared with the IC 50 of anchoragedependent growth, which was 20 M.
Discussion
We established and characterized a novel astrocytoma cell line, TM-31, from a malignant astrocytoma excised in a patient with NF1. The initial biopsy specimen had histological features of anaplastic astrocytoma, but the final diagnosis of glioblastoma multiforme was established at autopsy. This discrepancy may have been due to the regional heterogeneity of glioblastoma multiforme. The original tumor specimen was shown to be positive for GFAP by immunohistochemical analysis. However, TM-31 cells at high passages lost this GFAP positivity according to the results of the immunocytochemical and immunoblot analyses, although they expressed vimentin and S-100 protein. Most astrocytoma cell lines that have been established thus far have lost GFAP positivity. 8, 9, 39 This phenomenon could be explained by "dedifferentiation" of the established glial cells or better in vitro adaptability of the GFAP-negative nonglial component of the original tumor specimen. 39 The TM-31 cells are transformed and immortalized, but they are neither highly malignant nor highly proliferative, as was evidenced by their lack of tumorigenicity in athymic mice, their relatively long in vitro doubling times, and their low clonogenicity in soft agar. 39 However, this cell line is immortalized and there is no finding of cell senescence. To the best of our knowledge, TM-31 is the first immortalized astrocytoma cell line to be derived from a tumor in a patient with NF1.
In the present study, a decreased level of neurofibromin was observed in TM-31 cells by immunoblot analysis. Although NF1 gene analysis of TM-31 cells remains to be elucidated, this finding is consistent with previous reports that astrocytomas, melanomas, neuroblastomas, schwannomas, and soft-tissue tumors in patients with NF1 lose their neurofibromin expression. 5, 11, 21, 43 Therefore, NF1 gene mutation is suggested in TM-31 cells. Consistent with other tumor suppressor genes, some spontaneous tumors including colon adenocarcinomas, astrocytomas, neuroblastomas, melanomas, and pheochromocytomas in individuals without NF1 also showed NF1 gene mutation or loss of NF1 expression. 1, 21, 23, 44 In contrast, increased NF1 gene expression was observed in sporadic astrocytomas in which elevated levels of activated Ras were also observed. 14, 37 This increase in neurofibromin expression is believed to be a result of positive feedback regulation of increased Ras activity, a futile attempt by these astrocytoma cells to downregulate Ras and reduce uncontrolled growth signals. 14 The TM-31 cells demonstrated a p53 mutation in exon 7, codon 238. Mutations in the evolutionarily conserved exons 5 through 8 of the tumor suppressor gene p53 are often detected in astrocytomas and in some NF-1-associated malignant tumors. 22, 30, 46 In malignant neurofibrosarcomas harbored by patients with NF1, it is hypothesized that tumor formation is the result of independent multistep genetic events including mutation of the NF1 gene at an early stage and accumulation of additional genetic abnormalities such as p53 mutation. 16, 22 However, there has been a conflicting report that no p53 mutation was observed in pilocytic astrocytomas and glioblastomas multiforme in patients with NF1. 18 In addition, no mutations were detected within exons 5 through 8 of the p53 in neurofibrosarcomas, some of which were NF1 derived. 24 Therefore, we assumed that mutations of p53 are not essential for the development of malignant tumors in patients with NF1, but in some tumors p53 mutation may play an important role in tumor progression.
The TM-31 cells displayed chemoresistance to ACNU. There are several factors affecting chemoresistance. It is known that MGMT activity is strongly involved in the ACNU resistance mechanism of tumor cells. 31 Thus it is likely that TM-31 cells may have a high level of MGMT activity. Mutation of p53 may also affect the chemoresistance of tumor cells. Wild-type p53 is thought to enhance chemosensitivity by promoting apoptosis via either transcriptional activation of proapoptotic genes such as bax or transcriptional repression of antiapoptotic genes such as bcl-2. 25, 32 Therefore, mutation of p53 might prevent apoptotic cell death and thus result in chemoresistance to some anticancer drugs. In this regard, the finding that TM-31 cells are very sensitive to cisplatin suggests that other factors such as MGMT activity, rather than p53 mutation, may play more important roles in ACNU chemoresistance. The TM-31 cells exhibited no morphological differentiation by ATRA or dbcAMP, which are well-known differentiation inducers. 38, 42 An important role for the NF1 gene in neuroectodermal and neural crest-derived cell differentiation has been postulated. 35, 40 In addition, it has been suggested that neurofibromin may function as a downstream effector of Ras in the differentiation pathway. Furthermore, it has been reported that phosphorylation of neurofibromin by cyclic adenosine monophosphate-dependent protein kinase A is important in cellular differentiation signaling. 19 Thus it is possible that differentiation is interrupted by a neurofibromin abnormality and/or possible aberrant Ras activation in TM-31 cells. The molecular mechanism of this chemoresistance and resistance to morphological differentiation of TM-31 cells should be elucidated in the future.
Finally, pharmacological inhibition of farnesyltransferase of the Ras oncoprotein led to decreased proliferative activity and inhibition of anchorage-independent growth of TM-31 cells. These results are consistent with the decreased neurofibromin expression and suggest that Ras activation is the major event in growth signaling and the transformed phenotype of TM-31 cells. Farnesyltransferase inhibitor may be potentially important as a novel antiproliferative therapy for tumors derived from NF1. Taken together, these results show that TM-31 cells are a transformed astrocytic tumor cell line derived from a tumor excised in a patient with NF1, which may be of great value in future studies on diverse aspects of NF1 tumor biology and glial tumorigenesis. 
